[HTML][HTML] Tumor and microenvironment evolution during immunotherapy with nivolumab
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
[HTML][HTML] Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba… - Cell, 2017 - cell.com
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba… - Cell, 2017 - europepmc.org
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
[引用][C] Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba… - Cell, 2017 - cir.nii.ac.jp
[HTML][HTML] Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba… - Cell, 2017 - Elsevier
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
[PDF][PDF] Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba… - Cell, 2017 - academia.edu
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
N Riaz, JJ Havel, V Makarov, A Desrichard… - …, 2017 - providence.elsevierpure.com
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
[HTML][HTML] Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba… - Cell, 2017 - ncbi.nlm.nih.gov
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard… - Cell, 2017 - pubmed.ncbi.nlm.nih.gov
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba… - Cell, 2017 - pure.johnshopkins.edu
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …